KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $37.8 billion.

  • Regeneron Pharmaceuticals' Liabilities and Shareholders Equity rose 7.28% to $40.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $153.7 billion, marking a year-over-year increase of 9.02%. This contributed to the annual value of $37.8 billion for FY2024, which is 14.15% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Liabilities and Shareholders Equity of $37.8 billion as of FY2024, which was up 14.15% from $33.1 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $37.8 billion during FY2024, and its lowest value of $17.2 billion during FY2020.
  • In the last 3 years, Regeneron Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $33.1 billion in 2023 and averaged $33.4 billion.
  • Data for Regeneron Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 48.19% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Liabilities and Shareholders Equity stood at $17.2 billion in 2020, then surged by 48.19% to $25.4 billion in 2021, then grew by 14.86% to $29.2 billion in 2022, then increased by 13.23% to $33.1 billion in 2023, then rose by 14.15% to $37.8 billion in 2024.